Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (71-80 of 272) with videos related to

Pageof 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 10, 2016
Development of molecularly targeted agents and immunotherapies in small cell lung cancerAdam Sharp, Jaishree Bhosle, Fatma Abdelraouf, et al.
Drugs|April 6, 2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung CancerSaoirse O Dolly, Dearbhaile C Collins, Raghav Sundar, et al.
JTO Clinical and Research Reports|November 30, 2023
Salvage Therapy With Selpercatinib for <i>RET</i>-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case ReportPaolo D d'Arienzo, Niamh Cunningham, Hazel O'Sullivan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancerNadza Tokaca, Andrew Wotherspoon, Andrew G Nicholson, et al.
Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2020
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR MutationsAntonio Passaro, Tony Mok, Solange Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2020
EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to OsimertinibNiamh Coleman, David Woolf, Liam Welsh, et al.
Seminars in Oncology|July 9, 2019
Targeting angiogenesis for patients with unresectable malignant pleural mesotheliomaAnne Tsao, Takashi Nakano, Anna K Nowak, et al.
JCO Oncology Practice|August 26, 2020
Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> AmplificationNadza Tokaca, Wanyuan Cui, Stephen Hazell, et al.
Future Oncology (London, England)|August 23, 2021
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)Sanjay Popat, Geoffrey Liu, Shun Lu, et al.
Pageof 28

Showing results (71-80 of 272) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|April 10, 2016
Development of molecularly targeted agents and immunotherapies in small cell lung cancerAdam Sharp, Jaishree Bhosle, Fatma Abdelraouf, et al.
Drugs|April 6, 2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung CancerSaoirse O Dolly, Dearbhaile C Collins, Raghav Sundar, et al.
JTO Clinical and Research Reports|November 30, 2023
Salvage Therapy With Selpercatinib for <i>RET</i>-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case ReportPaolo D d'Arienzo, Niamh Cunningham, Hazel O'Sullivan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancerNadza Tokaca, Andrew Wotherspoon, Andrew G Nicholson, et al.
Pharmacoeconomics|June 9, 2023
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key DriversAurelie Meunier, Louise Longworth, Manuel Gomes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2020
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR MutationsAntonio Passaro, Tony Mok, Solange Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2020
EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to OsimertinibNiamh Coleman, David Woolf, Liam Welsh, et al.
Seminars in Oncology|July 9, 2019
Targeting angiogenesis for patients with unresectable malignant pleural mesotheliomaAnne Tsao, Takashi Nakano, Anna K Nowak, et al.
JCO Oncology Practice|August 26, 2020
Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> AmplificationNadza Tokaca, Wanyuan Cui, Stephen Hazell, et al.
Future Oncology (London, England)|August 23, 2021
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)Sanjay Popat, Geoffrey Liu, Shun Lu, et al.
Pageof 28